13 results about "Hematologic disorders" patented technology

The invention relates to the technical field of hematopoietic reconstruction, in particular to application of costal cartilage derived stem cells and costal cartilage derived stem cells combined with pluripotent progenitor cells, hematopoietic stem cells or cyclosporine in preparation of a preparation for hematopoietic reconstruction. The costal cartilage derived stem cells (CD45-CD51 +) are derived from costal cartilage and have remarkable ecological niche recovery capability. When the cells are used alone or combined with hematopoietic stem cells and pluripotent progenitor cells, the hematopoietic function can be enhanced. The costal cartilage-derived stem cells are directionally differentiated into important supporting cells forming bone marrow ecological niche, secrete hematopoietic cell factors and protect hematopoietic stem / progenitor cells. In treatment of aplastic anemia, costal cartilage-derived stem cells and cyclosporin A have a synergistic effect, and immune-mediated bone marrow failure is improved through dual mechanisms. According to the technical scheme, the technical problem that the effect of treating bone marrow failure and promoting hematopoietic reconstruction by hematopoietic stem cell transplantation is not ideal is solved, and a new way is opened up for treating bone marrow failure and blood system diseases.

Methods for administering isolated anti-CD38 antibodies subcutaneously at low doses are described. These methods provide effective treatment for autoimmune diseases and certain cancers, including hematological disorders. Unit-dose formulations for anti-CD38 antibodies are also described.

The application discloses a monoclonal antibody specifically targeting CD177 and related uses thereof, the amino acid sequences of CDR-H1, CDR-H2 and CDR-H3 in the heavy chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO: 6-8, the amino acid sequences of CDR-L1, CDR-L2 and CDR-L3 in the light chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO: 9-11, the monoclonal antibody has high affinity and specificity to CD177, can be used in the development of a high-sensitivity detection kit, helps early diagnosis of blood system diseases and autoimmune diseases, provides a reliable tool for CD177 pathological mechanism research, can lay an epitope foundation for subsequent development of therapeutic antibodies, and has outstanding clinical application value and scientific research conversion potential.

Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating cancers or hematologic disorders.

The invention provides an anticoagulant composition as well as a preparation method, a related product and application thereof. Belongs to the technical field of medicine. The anticoagulant composition comprises hydroxysafflor yellow A and dehydrated safflor yellow B in a mass ratio of (0.5-0.75): 1. The anticoagulant composition provided by the invention can synergistically prolong APTT, inhibit FXa activity and inhibit zebra fish thrombosis, and is expected to develop drugs with better curative effects for treating or preventing cardiovascular diseases, cerebrovascular diseases, cerebral apoplexy, venous thromboembolic diseases and blood system diseases.

The application discloses application of CREG1 protein in preparation of medicines or reagents for inhibiting hematopoietic stem cell aging, and belongs to the field of biological medicines. The application first finds that the CREG1 protein has the function of inhibiting hematopoietic stem cell aging (including inhibiting hematopoietic stem cell proliferation abnormality, maintaining hematopoietic stem cell resting state, reducing hematopoietic stem cell DNA damage, and weakening hematopoietic stem cell myeloid differentiation tendency). Therefore, the CREG1 protein has the prospect of being developed into the medicines or reagents for inhibiting hematopoietic stem cell aging, and also has the prospect of being developed into the medicines for improving the immune function decline, anemia, bone marrow hypofunction or blood system diseases caused by hematopoietic stem cell aging.

The present disclosure relates to anti-SAA antibodies or fragments thereof, such as antibodies against human SAA1 or fragments thereof, that may be used in various therapeutic, prophylactic and diagnostic methods. The present antibodies or fragments thereof may be used to treat hematologic disorders such as acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome.

The present application relates to the field of biotechnology, in particular, the application of E4BP4 in hematological diseases such as multiple myeloma. The present application proves that E4BP4 can be used as a potential biomarker and prognostic indicator for predicting the development of multiple myeloma, which is helpful for the treatment of multiple myeloma. Moreover, the E4BP4 protein can be used in the preparation of MM promoting reagents, which can be further used in the amplification of MM cells, the preparation of MM tumor metastasis models, the screening of MM treatment drugs and the like. After knocking down E4BP4, autophagy is induced and MM cell apoptosis is promoted, thereby enhancing the anti-myeloma effect of dexamethasone on MM. E4BP4 inhibitory drugs can be used as anti-myeloma drugs together with dexamethasone.

The application provides an aurone compound and a medical use thereof, and is an aurone compound and application thereof in preparation of prevention and treatment of myelosuppression or blood system diseases. The aurone compound provided by the application can significantly improve the myelosuppression state caused by ruxolitinib and radiotherapy, can restore the generation of red blood cells after irradiation and use of ruxolitinib, and has a significant effect on the recovery of white blood cells, especially neutrophils and lymphocytes, of mice after irradiation. The application provides a new potential drug for the treatment of myelosuppression or blood system diseases.

The present disclosure provides epitopes of CD45, and binding agents such as antibodies, antibody fragments, peptides, and small molecules capable of binding to those epitopes. The present disclosure also provides methods of treating cancers, hematological diseases and disorders, and immune diseases and disorders, using these binding agents.

The invention provides a method for regulating and controlling hematopoietic balance based on a Jak2 / Stat3-Hif1a signal channel and application of the method, and belongs to the field of biotechnology and medicine. According to the method, by regulating and controlling a Jak2 / Stat3-Hif1a signal channel, hematopoietic system unbalance caused by factors such as acute inflammation or acute hypoxia is intervened or reversed. Aiming at the problems that in the prior art, mechanism cognition is not clear, intervention targets are not clear, pathway relevance research is insufficient and the like, the molecular mechanism of acute inflammation affecting hematopoietic balance is deeply explored, and the internal relation of a Jak2 / Stat3 pathway and Hif1alpha for regulating and controlling hematopoietic balance under the acute stress condition is disclosed. The invention can be applied to preparation of medicines for treating blood system diseases caused by factors such as acute inflammation and hypoxia, particularly provides a targeted intervention strategy for accurately correcting hematopoietic lineage migration aiming at diseases such as sepsis-related anemia, and has important clinical application value.

The present invention relates to the use of the proportion of plasma cells, lymphocytes or blasts expressing GLUT1 among total plasma cells, lymphocytes or blasts in a method for stratifying prognosis of subjects suffering from a hematologic disorder, and in a method for determining whether a subject suffering from a hematologic disorder will achieve or is achieving a response with a modulator of the BCL-2 family proteins. The present invention also relates to a kit for detecting GLUT1, and optionally ASCT2, for implementing one of these methods.